Does lixisenatide reduce major cardiovascular events in patients with type 2 diabetes and a recent acute coronary syndrome?
In patients with type 2 diabetes and recent acute coronary syndrome, adding lixisenatide to usual care does not significantly reduce major cardiovascular events.
In patients with type 2 diabetes and a recent acute coronary syndrome, the addition of lixisenatide to usual care did not significantly alter the rate of major cardiovascular events or other serious adverse events. (Funded by Sanofi; ELIXA ClinicalTrials.gov number, NCT01147250.).
Pfeffer et al. (Wed,) studied this question.